ncIdentally discovered brain lesions are identified as imaging abnormalities detected in patients who undergo brain imaging for an unrelated medical issue. The likelihood of encountering such "incidentalomas" is rising due in part to advances in imaging technology and the increasing number of people around the world who have access to modern diagnostic imaging. The incidence of incidental findings on brain imaging ranges from 0.05% to 3% among the healthy adult population. 2, 13, 17, 18, 21, 26 These incidental findings may be a consequence of radiological screening of asymptomatic patients for other CNS lesions or research, the result of imaging following trauma, or in-ABBREVIATIONS EOR = extent of resection; FLAIR = fluid attenuation inversion recovery; iLGG = incidental low-grade glioma; KPS = Karnofsky Performance Status; LGG = low-grade glioma; MPFS = malignant progression-free survival; OS = overall survival; PFS = progression-free survival; ROI = region of interest; SD = standard deviation; SEM = standard error of the mean. LGGs has become more frequent due to the vast increase in access to medical imaging technology. While management of these lesions remains controversial, early surgery has been suggested to improve outcome. The authors set out to identify and review the characteristics and surgical outcomes of patients who underwent surgical intervention for incidental LGG. METHODS All cases of LGG surgically treated between 2004 and 2016 at the authors' institution were analyzed to identify those that were discovered incidentally. Patients with incidentally discovered LGGs were identified, and their cases were retrospectively reviewed. An "incidental" finding was defined as an abnormality on imaging that was obtained for a reason not attributable to the glioma, such as trauma, headache, screening, or research participation. Kaplan-Meier analysis was performed to determine actuarial rates of overall survival, progression-free survival, and malignant progression-free survival. RESULTS In 34 (6.8%) of 501 adult patients who underwent surgery for LGG, the tumors were discovered incidentally. Headache (26%, n = 9) and screening (21%, n = 7) were the most common indications for brain imaging in this group. Four of these 34 patients had initial biopsy after the tumor was identified on imaging. In 5 cases, the patients opted for immediate resection; the remaining cases were managed with a "watch-and-wait" approach, with intervention undertaken only after radiological or clinical evidence of disease progression. The mean duration of follow-up for all 34 cases was 5 years. Twelve patients (35.3%) had disease progression, with an average time to progression of 43.8 months (range 3-105 months). There were 5 cases (14.7%) of malignant progression and 4 deaths (11.8%). Oligodendroglioma was diagnosed in 16 cases (47%) and astrocytoma in 15 (44%). Twenty-five patients (74%) had IDH1 mutation and demonstrated prolonged survival. Only 2 patients had mild surgery-related complications, and 16 patients (47%) developed epilepsy during the course of the disease. CONCLUSIONS In this retrospective analysis of cases of incidentally discovered LGGs, the tumors were surgically removed with minimal surgical risk. In patients with incidental LGGs there is improved overall survival relative to median survival for patients with symptomatic LGGS, which is likely attributable to the underlying favorable biology of the disease indicated by the presence of IDH1 mutation in 74% of the cases.
vestigation for nonspecific symptoms. Infiltrating gliomas are an important group of incidental lesions discovered on brain imaging due to the significant impact they will ultimately impose on individuals who harbor them.
Growing evidence in the literature supports the significantly positive impact of maximal safe resection on overall survival (OS) in patients with symptomatic glioma. The management of incidental gliomas in asymptomatic patients remains controversial, posing a significant dilemma to both the surgeon and the patient. The poorly understood natural history of these lesions and paucity of literature about these tumors contribute to this dilemma. Many neurosurgeons adopt a "watch-and-wait" approach 19, 22 and intervene only when clinical symptoms manifest or there is radiological evidence of disease progression. A growing number of neurosurgeons with special interest in neurooncology, however, believe that early resection allows for greater extent of resection resulting in longer survival. 1, 11 Pallud et al. have demonstrated that surgical excision of incidental low-grade gliomas (iLGGs) increases survival. 19 Also, in their most recent case report, Cochereau et al. illustrate the fact that there can be acute malignant transformation of iLGGs even when the patient remains symptom free. 7 We set out to review a series of cases of iLGGs treated during a period when the general approach at our institution was "watch-and-wait" to determine the characteristics of these tumors and treatment outcomes.
Methods
This study was approved by the Health Research Ethics Board of Alberta Cancer Committee at the University of Calgary.
Patient Selection
We retrospectively identified adult patients (age ≥ 18 years) who underwent surgery at the Foothills Medical Center for low-grade infiltrative glioma between April 2004 and April 2016 and had at least 6 months of postoperative follow-up. Surgery was performed by 8 different neurosurgeons. Patient electronic charts, including outpatient neuro-oncology notes, were reviewed for clinical presenting history, radiological images, operative report, and hospital course. Patients with incidentally discovered LGG were selected. An "incidental" glioma is defined in this study as the finding of a glioma on brain imaging that was obtained for reasons or neurological symptoms not attributable to the tumor, such as trauma, headache without associated mass effect or sign of intracranial hypertension, screening for other neurological diseases, or research purposes. Histopathological diagnosis and tumor grade based on 2007 WHO guidelines as well as molecular genetic profiles (including MGMT, IDH, ATRX, P53, and 1p19q co-deletion status) were noted from medical records. WHO Grade II was confirmed for all patients included in the study. Patients who were symptomatic or had high-grade pathology (based on WHO criteria) were excluded.
Volumetric Analysis
Volumetric analysis of tumor volume, growth rate, and 
Primary Outcome Measure
Outcome measures were assessed and defined as follows. Overall survival (OS) was defined as time from initial resection to death. Progression-free survival (PFS) was defined as time from initial resection to evidence of tumor enlargement on follow-up MRI. Malignant progressionfree survival (MPFS) was defined as time from initial resection to evidence of contrast enhancement on follow-up MRI or higher-grade histopathology from subsequent surgery. Patients with known progression and/or malignant transformation or death were censored as of their last MRI date or last clinic follow-up date, respectively.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 7 software. Frequency distribution and summary statistics were calculated for all variables. For categorical variables, cross-tabulation was generated and Wilcoxon and Fisher tests were used to compare distributions. Statistical significance was defined as p < 0.05. Survival (OS, PFS, and MPFS) was estimated using the Kaplan-Meier method. Results of Kaplan-Meier analysis are reported as means with standard error of the mean (SEM). Comparison of survival curves according to various parameters was performed using the Mantel-Cox test. A univariate Cox proportional hazards model was used to assess the prognostic significance of multiple variables with respect to survival.
Results

Patient Demographics
A total of 501 patients with newly diagnosed LGG were treated at our institution between April 2004 and April 2016. Thirty-four patients (6.8%) from this population met the study inclusion criteria. Characteristics of these 34 patients are summarized in Table 1 . The group included 17 men and 17 women, and their mean age at tumor discovery was 40.8 years (standard deviation [SD] 12.5 years). Headache was the most common indication for brain imaging leading to the diagnosis of glioma (26%, n = 9), followed closely by screening (21%, n = 7). Other reasons for imaging included trauma, syncope, dizziness, hearing loss, acute psychosis, and nonspecific neurological signs that did not localize to the site of the glioma. Screening was done for family history of cerebral aneurysm, moyamoya disease, neurofibromatosis, and multiple sclerosis. One patient was screened following resection of a spinal schwannoma and cytogenetic test confirming neurofibromatosis Type 2. In patients presenting with headaches, the headaches were usually "migrainous" and long-standing in nature, without changes in character over time. Furthermore, worrisome symptoms such as nausea/vomiting or worsening in the morning, as typically described in headache due to neoplasm, were not present, and imaging typically did not demonstrate vasogenic edema or mass effect. Also, the size of the tumors among iLGG patients presenting with headaches, although variable, was generally smaller at the time of diagnosis than the size of the tumors in the rest of this patient cohort. The mean time from discovery of an incidental glioma to surgery was 27.6 months (range 0-161 months). In general, during this period patients with iLGGs were followed with MRI surveillance and underwent resection once changes were noted on imaging or they became symptomatic. Five patients opted for early resection rather than surveillance, but the remaining patients only underwent resection after evidence of progression was detected on follow-up imaging. Four patients underwent biopsy for definitive diagnosis. No patient had documented neurological deficit preoperatively; the preoperative Karnofsky Performance Status (KPS) score was 100 in 22 patients (65%) and 90 in 12 (35%).
Tumor Characteristics
We hypothesized that iLGGs would be smaller in size and located predominantly in nondominant locations. Imaging review demonstrated that the frontal lobe was the most common location (52.9%, n = 18) and that 19 tumors ), as depicted in Fig. 1A . All but 5 patients had a volume increase on preoperative imaging compared with imaging at diagnosis (Fig. 1B) ). Within the patient cohort, there was a wide variation in the rate of change in tumor size, ranging from rapid growth within months (Fig. 1C) to slow growth over several years (Fig. 1D ).
Surgical Results
Other than 2 patients who underwent an awake craniotomy, all patients were operated on under general anesthesia. There was no operative death recorded. Postoperatively 1 patient had transient akinetic mutism, which resolved within 48 hours, prior to discharge from the hospital. Another patient suffered a middle cerebral artery perforator infarct in the capsuloganglionic region, leaving him with mild hemiparesis and dysphasia. The mean postoperative hospital stay was 3 days (range 1-7 days). Eleven patients (32%) were discharged with a KPS score of 90, and 23 (68%) were discharged with a score of 100. The EOR was 100% in 8 cases (23.5%), 75%-99% in 11 (32.4%), 50%-74% in 9 (26.5%), and 0%-49% in 6 (17.6%). Histopathological review confirmed LGG in all 34 cases. All but 2 patients had molecular genetic testing, including assessment of MGMT, IDH, P53, ATRX, and 1p19q co-deletion status. Based on this knowledge and using the 2016 WHO classification of CNS tumors, 13 patients (38.2%) had oligodendroglioma, IDH mutant and 1p19q co-deleted; 3 (8.8%) had oligodendroglioma, not otherwise specified; 12 (35.3%) had diffuse astrocytoma, IDH mutant; and 3 (8.8%) had diffuse astrocytoma, IDH wild type. No molecular genetic testing was performed in 3 patients; oligoastrocytoma was diagnosed in 2 of these patients and ganglioglioma in 1 patient (Table 2) . Sixteen patients (47%) developed early (< 3 months after surgery) or delayed (≥ 3 months after surgery) postoperative seizure disorder. Patients with diffuse astrocytoma had a higher incidence of developing postoperative seizures than did those with oligodendroglioma (Table 3) .
Survival
The mean duration of follow-up was 5.1 years (range 0.5-12 years). Twelve patients (35.3%) had disease pro- gression; the average time to progression in these cases was 43.8 months (range 3-105 months) ( Table 4 ). There were 9 cases of malignant transformation (26.5%) and 4 deaths (11.8%). All but one of the patients who died in the study had malignant transformation from LGG to glioblastoma; the single exception was a patient who died of Stage IV pancreatic cancer. Eight patients underwent repeat resection, and 3 of these patients received adjuvant temozolomide and/or radiation therapy. Kaplan-Meier estimates of OS, PFS, and MPFS are shown in Fig. 2 . The 10-year survival rate was greater than 80% (with only 4 deaths, representing 11.8% of the patient cohort, median survival could not be estimated). The median survival times for PFS and MPFS, however, were approximately 6 and 9 years. Survival (OS, PFS, MPFS) curves were compared according to EOR, histopathology (Fig. 3) , and IDH mutation status (Fig. 4) . Although no patient with 100% EOR had died when the data were analyzed, there was no statistically significant association between EOR and OS (p = 0.82). Oligodendroglioma and IDH mutation were associated with survival benefit (p < 0.0001).
Discussion
Incidental low-grade glioma (iLGG) is a WHO Grade II glioma discovered on brain imaging performed for a reason not attributable to the lesion. The incidence of iLGG has been shown to range from 0.025% to 0.3% in population-based imaging studies, 2, 13, 18, 21, 26 and thus these lesions account for 3%-5% of all LGGs. 10, 17 In our study we found that iLGGs accounted for 6.8% of cases in our group of patients with LGGs, a similar proportion to that reported in the literature. Furthermore, 94% of our patients' tumors were oligodendrogliomas and/or astrocytomas. IDH mutation was present in 74% and was significantly associated with improved survival (OS, PFS, and MPFS). These results are in keeping with results of previous studies evaluating genetics and mutations present in tissues from resected iLGGs. The ubiquitous use of brain imaging technology in the developed world, and increasing access to brain imaging worldwide, will likely lead to a rise in the reported incidence of iLGGs, most of which harbor IDH1 mutation. 9, 17 Consequently, neurosurgeons will be increasingly faced with the dilemma of how to care for patients with iLGGs.
Due to the relative rarity of iLGG, there is a paucity of data about the natural history of this disease before symptom onset together with the appropriate treatment approach and its timing. Recent studies have demonstrated that iLGGs grow at a velocity similar to their symptomatic counterparts. 7, 20 Not only do iLGGs grow over time, they may also undergo malignant degeneration even in asymptomatic patients. 8, 12 Our results demonstrate that tumor volumes increase by about 20 cm 3 over an average of 28 months, and in 1 extreme case rapid progression with malignant transformation occurred that ultimately led to the patient's demise (Fig. 4) . When considering management options, the question of whether patients with iLGG are truly asymptomatic must be addressed. In a recent study of neuropsychological disturbance in patients with iLGG, Cochereau et al. reported that 60% of the patients in their study had neurocognitive dysfunction, suggesting that patients may actually be symptomatic when more sensitive tests are employed at the time of diagnosis. 6 Resection for the initial presentation of symptomatic LGG is widely accepted, and maximal safe resection is a crucial factor in determining survival. 5, 14, 16, 24 Incidental LGGs are believed to represent an earlier step in the pathological progression of LGG. Various investigators (Duffau, 8 Pallud et al., 19 and Potts et al.
20
) have demonstrated that resection of iLGGs leads to an improved survival compared with survival in symptomatic cohorts. This finding was attributable to low tumor volume, noneloquent location, and greater rates of EOR in iLGGs compared with symptomatic LGGs. Our study also showed survival benefit of resection, with 80% of patients alive at a mean follow-up period of 5 years. About 35% of the 34 patients included in the study had disease progression, and about 26% had malignant transformation. Surgery-related complications were minimal, with 2 patients suffering mild nondisabling strokes and another experiencing transient akinetic mutism. In light of these findings, together with recent evidence demonstrating survival benefit for resection of symptomatic LGGs, 
FIG. 3.
Correlation of OS with EOR (p = 0.82, log-rank test) (A), histopathology (p = 0.07, log-rank test) (B), and histopathology and IDH mutation status (p < 0.0001, log-rank test) (C). Oligoastrocytoma is categorized as astrocytoma in this graph. The case of ganglioglioma was omitted from this analysis. Astro = astrocytoma; IDHmu = IDH mutant; IDHwt = IDH wild type; NOS = not otherwise specified; Oligo = oligodendroglioma. resective surgery should be considered as a management option for iLGGs.
Seizures are a frequent consequence and initial presenting symptom of LGGs. 3, 4, 23, 25 Knowledge about the risk of seizures in iLGGs either at presentation or after resection is limited. Lima and Duffau reported seizures in 2 of 21 patients with iLGG who underwent awake surgery. 15 Our study demonstrated a higher proportion of patients (16 [47%] of 34) who experienced postoperative seizures. In 6 of these patients, the seizures occurred during the early postoperative period (< 3 months after surgery) and in 10 they developed during the late postoperative period (> 3 months after surgery). Patients with astrocytic tumors were more likely to develop seizures. These postoperative seizures could be explained by recurrent disease and may simply relate to the natural history of the disease or could perhaps be a functional consequence of resection.
The main limitations of this study are the small sample size and small number of events (i.e., deaths) recorded. Both are due to the rarity of iLGGs. Also due to the limitation of our study design, comparative efficacy of early surgery in iLGGs could not be assessed. Our study failed to demonstrate a statistically significant survival benefit with greater EOR and histopathology, contrary to current knowledge about LGGs, although at the time of manuscript preparation there was no recorded death of any of our patients in whom an EOR of 100% was achieved. We believe these results reflect the small sample size captured by our study.
Conclusions
We demonstrate that iLGGs are not quiescent, even in patients thought to remain asymptomatic while harboring these lesions. Importantly, resection can be safely performed without significant consequence to patient performance status and should be favored over a "watchand-wait" approach. Both early and delayed postoperative seizures occur frequently in patients with iLGGs and may be a consequence of treatment or may simply reflect the natural history of LGG. The majority of iLGGs harbor IDH1 mutation, leading to delayed disease progression, longer time before malignant transformation, and improved OS. Balancing early surgical intervention with the principle of primum non nocere should be a primary consideration when individualizing treatment for patients diagnosed with iLGGs.
